Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Bachir, J."'
Autor:
Witherby, Sabrina ⁎, †, Rizack, Tina ⁎, Sakr, Bachir J. ⁎, Legare, Robert D. ⁎, Sikov, William M. ⁎, ⁎
Publikováno v:
In Seminars in Radiation Oncology January 2016 26(1):59-70
Autor:
Christine M Emmick, Ashley Stuckey, Marlene Cutitar, Jennifer Gass, Sabrina M Witherby, Robert D. Legare, Mary Anne Fenton, William M. Sikov, Mary L Lopresti, Rochelle Strenger, Jessica J Bian, Theresa A. Graves, David A Edmondson, Sonali V Pandya, Bachir J. Sakr, Donald S Dizon, Adam J. Olszewski
Publikováno v:
Breast Cancer Research and Treatment. 189:93-101
In HER2-positive breast cancer (HER2+ BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response (pCR) rates. Anthracycline-free NACT regimens avoid toxicities associated with anthracyclines, but e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0f9eff5650637f568bb00390d174e1f
https://doi.org/10.1007/s10549-021-06266-9
https://doi.org/10.1007/s10549-021-06266-9
Autor:
Robison, Katina 1, ∗, Olson, Courtney 2, Sakr, Bachir J. 1, Rizack, Tina 1, Legare, Robert 1, Stuckey, Ashley 1, Granai, C.O. 1, Dizon, Don S. 3
Publikováno v:
In Clinical Ovarian and Other Gynecologic Cancer December 2013 6(1-2):21-24
Autor:
Migdady, Yazan a, b, Sakr, Bachir J. a, c, Sikov, William M. a, d, Olszewski, Adam J. a, b, ∗
Publikováno v:
In The Breast October 2013 22(5):793-798
Autor:
David A Edmondson, Sonali V Pandya, Marlene Cutitar, Ashley Stuckey, Rochelle Strenger, Don S. Dizon, Sabrina M Witherby, Bachir J. Sakr, William M. Sikov, Mary Anne Fenton, Jennifer Gass, Mary L Lopresti, Robert D. Legare, Theresa A. Graves, Christine M Emmick, Adam J. Olszewski, Jessica J Bian
Publikováno v:
Cancer Research. 80:P2-16
In H+BC, neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response (pCR) rates, but the most common anthracycline-free regimen, every 3-week docetaxel and Cb with T and P (TCHP), causes significant hem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::193ef7664332f0861e75edce59f414ef
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-19
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-19
Autor:
Kuroki, Lindsay a, Stuckey, Ashley a, b, ⁎, Hirway, Priya a, Raker, Christina A. a, Bandera, Christina A. a, b, DiSilvestro, Paul A. a, b, Granai, Cornelius O. a, b, Legare, Robert D. a, b, Sakr, Bachir J. a, b, Dizon, Don S. a, b
Publikováno v:
In Gynecologic Oncology 2010 116(3):295-300
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Seminars in Radiation Oncology. 26:59-70
Standard management of early stage and advanced breast cancer has been improved over the past few years by knowledge gained about the biology of the disease, results from a number of eagerly anticipated clinical trials and the development of novel ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::226c05ab552525484a7f4dcf184aa79c
https://doi.org/10.1016/j.semradonc.2015.09.005
https://doi.org/10.1016/j.semradonc.2015.09.005
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Susan K. Boolbol, Adam J. Olszewski, Paula Klein, Theresa Shao, Yazan Migdady, K. Boachie-Adjei, Bachir J. Sakr, William M. Sikov
Publikováno v:
Breast Cancer Research and Treatment. 138:215-223
Previous studies have reported higher recurrence rates in T1a/b N0 breast cancers characterized by high-risk biology (HER2+ or triple-negative), but the benefits of adjuvant chemotherapy in these patients have not been established. This study was des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::141f3cc0dfbaccb01ae115f4d8224f3d
https://doi.org/10.1007/s10549-013-2423-3
https://doi.org/10.1007/s10549-013-2423-3